Hologic, Inc. $HOLX Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,096,224 shares of the medical equipment provider’s stock after selling 144,403 shares during the period. Alliancebernstein L.P. owned 0.94% of Hologic worth $141,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its holdings in Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after purchasing an additional 8,227,318 shares in the last quarter. Invesco Ltd. raised its stake in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after acquiring an additional 3,505,828 shares in the last quarter. Norges Bank purchased a new stake in Hologic in the second quarter valued at $180,055,000. Balyasny Asset Management L.P. lifted its position in Hologic by 1,060.1% in the third quarter. Balyasny Asset Management L.P. now owns 1,218,352 shares of the medical equipment provider’s stock valued at $82,227,000 after acquiring an additional 1,113,330 shares during the last quarter. Finally, Black Creek Investment Management Inc. boosted its stake in Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after acquiring an additional 832,444 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

Shares of HOLX opened at $75.15 on Tuesday. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $75.75. The company has a market capitalization of $16.78 billion, a price-to-earnings ratio of 31.31, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. The firm has a 50-day simple moving average of $75.14 and a 200-day simple moving average of $72.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm earned $0.87 EPS. The business’s revenue was up 2.5% on a year-over-year basis. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HOLX. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the stock from $79.00 to $78.00 in a report on Monday, January 5th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research report on Friday, November 21st. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.